Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

Inclusion Criteria: * Must have a diagnosis of renal AML \> 3 cm confirmed on pre-enrollment Dynamic Contrast Enhanced MRI (DCE-MRI) * Must not have received any prior treatment for AML * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Absolute neutrophil count \>= 1,500/ microliter (mcL) * Hemoglobin \>=10 g/dL * Platelets \>= 100,000/ mcL * international normalized ratio (INR) \<= 1.2 X Upper limit Normal (ULN) * activated partial thromboplastin time (aPTT) \<= 1.2 X ULN * aspartate aminotransferase (AST) / alanine transaminase (ALT) \<= 2.5 X ULN * Total bilirubin \<= 2.0mg/dL * Renal Function epidermal growth factor receptor (eGFR) \>= 30 mL/min via calculated creatinine clearance * Fasting serum cholesterol \<= 300 mg/dL OR \<= 7.75 mmol/L AND fasting triglycerides \<= 2.5x ULN. Exclusion Criteria: * History of tuberous sclerosis, LAM or any active malignancy * Treatment with any other investigational agents for any other disease * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product * Active diarrhea of any grade. * History of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study); prior hepatitis C infection * Presence of any active or ongoing infection. * Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function test (PFTs) * History of certain cardiovascular conditions within the past 6 months * History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure. * History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. * Corrected QT interval (QTc) \> 480 milliseconds * Poorly controlled hypertension, defined as systolic blood pressure (SBP) of \>= 140 millimeters of mercury(mmHg) or diastolic blood pressure (DBP) of \>= 90 mmHg. * Evidence of active bleeding or bleeding diathesis * Uncontrolled diabetes mellitus (defined by a Hgb A1c \>8) obtained within 14 days prior to registration. Optimal glucose control (Hgb A1c \<= 8) must be achieved before registration and monitored during protocol treatment * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. * Unable or unwilling to discontinue use of prohibited medications * Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug. * Administration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment. * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus * Prior or current use of systemic anti-vascular endothelial growth factor (VEGF) inhibitors, cytokines or mechanistic target of rapamycin (mTOR) inhibitors (e.g. interferon, interleukin 2). * Pregnant or nursing (lactating) women * Women of child-bearing potential (WOCBP) must use highly effective methods of contraception during the study and 8 weeks after. * Unable to obtain a contrast (gadolinium) based DCE MRI, including include patients with pacemakers, automatic implantable cardioverter/defibrillator (AICDs), non MRI compatible metallic implants or eGFR \<30. * Must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment * Must not be taking, nor plan to take while on protocol treatment, strong cytochrome P450 3A4 (CYP3A4) inhibitors, (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, fluvoxamine, nefazodone, nelfinavir, ritonavir) and/or strong CYP3A4 inducers (e.g. phenytoin, rifampin, rifabutin) within 14 days prior to randomization. * History of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for \>= 3 years * Childs-Pugh A-C liver disease (Appendix II)